Beijing Beilu Pharmaceutical Co., Ltd. (SHE:300016)
China · Delayed Price · Currency is CNY 9.56
+0.18 (1.92%)
Sep 30, 2026, 3:04 PM CST
SHE:300016 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 5,561 | 4,469 | 3,050 | 3,503 | 3,208 | 4,523 | |
Market Cap Growth | 15.55% | 46.53% | -12.92% | 9.20% | -29.09% | -4.32% |
Enterprise Value | 5,411 | 4,423 | 3,388 | 3,635 | 3,239 | 4,391 |
Last Close Price | 9.56 | 7.89 | 6.12 | 7.02 | 6.36 | 8.86 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 36.91 | 48.19 | 223.42 | - | 284.26 | 36.04 |
Forward PE | - | 19.22 | 19.22 | 19.22 | 19.22 | 19.22 |
PS Ratio | 4.30 | 3.71 | 3.10 | 3.93 | 4.19 | 5.26 |
PB Ratio | 2.09 | 1.85 | 1.67 | 1.96 | 1.67 | 2.17 |
P/TBV Ratio | 2.42 | 2.17 | 2.09 | 2.30 | 1.98 | 2.71 |
P/FCF Ratio | 110.46 | - | 49.49 | - | 128.15 | - |
P/OCF Ratio | 23.83 | 28.55 | 18.71 | 59.91 | 25.10 | 41.60 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 4.18 | 3.67 | 3.45 | 4.08 | 4.23 | 5.11 |
EV/EBITDA Ratio | 23.81 | 24.20 | 23.46 | 64.58 | 46.41 | 23.08 |
EV/EBIT Ratio | 41.48 | 50.34 | 63.64 | - | - | 34.43 |
EV/FCF Ratio | 107.48 | - | 54.97 | - | 129.42 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.21 | 0.21 | 0.44 | 0.44 | 0.34 | 0.28 |
Debt / EBITDA Ratio | 2.50 | 2.75 | 5.37 | 13.30 | 8.92 | 3.02 |
Debt / FCF Ratio | 11.28 | - | 12.94 | - | 25.84 | - |
Net Debt / Equity Ratio | -0.12 | -0.07 | 0.10 | 0.02 | -0.06 | -0.15 |
Net Debt / EBITDA Ratio | -1.39 | -0.92 | 1.31 | 0.75 | -1.72 | -1.68 |
Net Debt / FCF Ratio | -6.25 | 2.71 | 3.07 | -0.49 | -4.79 | 8.18 |
Asset Turnover | 0.38 | 0.38 | 0.34 | 0.32 | 0.27 | 0.30 |
Inventory Turnover | 1.84 | 1.78 | 1.73 | 1.86 | 1.39 | 1.79 |
Quick Ratio | 1.88 | 1.65 | 1.74 | 2.63 | 2.93 | 3.65 |
Current Ratio | 2.64 | 2.40 | 2.57 | 3.33 | 3.89 | 4.57 |
Return on Equity (ROE) | 6.50% | 4.17% | 0.01% | -4.49% | -0.23% | 5.54% |
Return on Assets (ROA) | 2.40% | 1.74% | 1.15% | -0.55% | -0.11% | 2.77% |
Return on Invested Capital (ROIC) | 4.66% | 3.36% | 2.77% | -1.38% | -0.29% | 6.87% |
Return on Capital Employed (ROCE) | 4.40% | 3.20% | 2.10% | -1.00% | -0.20% | 4.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 2.56% | 2.08% | 0.45% | -2.05% | 0.35% | 2.77% |
FCF Yield | 0.91% | -1.39% | 2.02% | -2.46% | 0.78% | -0.86% |
Dividend Yield | 1.25% | - | 0.82% | - | 1.10% | 0.79% |
Payout Ratio | 10.36% | 40.35% | 153.09% | - | 465.63% | 35.77% |
Buyback Yield / Dilution | -19.50% | -13.21% | 4.88% | 15.21% | -16.87% | 0.52% |
Total Shareholder Return | -18.24% | -13.21% | 5.69% | 15.21% | -15.77% | 1.31% |